Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Poseida Therapeutics

Thumbnail
December 09, 2020

Ash 2020 movers – shorts roasting on an open fire

IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

Thumbnail
December 07, 2020

Ash 2020 – US academics target the Car-T relapse problem

Article image
Vantage logo
November 26, 2020

Ash 2020 cell therapy preview – the battle for recognition

With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.

Article image
Vantage logo
November 20, 2020

Precision’s Arcus gets a second endorsement

Article image
Vantage logo
December 09, 2019

Ash 2019 – for Car-T the bispecific antibody threat is real

As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.

Article image
Vantage logo
November 22, 2019

Allogene and the need for a reliable cell source

A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.

Article image
Vantage logo
October 09, 2019

SITC 2019 preview – Nextcure’s time to shine

The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.

Article image
Vantage logo
August 08, 2019

Autolus slams on the brakes in its Car

Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.

Article image
Vantage logo
July 11, 2019

Venture investing dips again for biopharma

The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.

Article image
Vantage logo
April 23, 2019

A Nasdaq float is scrapped, but for Poseida that’s great news

The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.

Article image
Vantage logo
March 31, 2019

AACR 2019 – Baylor sets the benchmark for Bellicum

A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.